Delivery Order SPE2DB22D3501-SPE2DB25FTG19

Award Date 10/24/24
Potential Completion Date 11/15/24
Potential Value $19K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,856.75 firm fixed-price delivery order is for the supply of TICOVAC 2.4 MCG/0.5 ML SYRINGE 0.5ML, a medical product, to support DLA's medical supply programs. The contract has no set-aside designation, indicating open competition. Amerisourcebergen also holds a $999,999,999 Indefinite Delivery Contract (IDC) with...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,856.75, is a Delivery Order with a Firm Fixed Price mechanism, awarded by the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the delivery of TICOVAC 2.4 MCG/0.5 ML SYRINGE 0.5ML, with a completion date of July 1, 2024. The contract is not designated with any set-aside requirements, indicating open competition....
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of TICOVAC 2.4 MCG/0.5 ML SYRINGE 0.5ML. The contract is a $1,850.16 firm-fixed-price delivery order with a period of performance through September 24, 2024. The award is not associated with a set-aside program. Amerisourcebergen, through its Corporate Office division, has been awarded numerous federal contracts by the DLA and other...
This federal contract award is for the delivery of TICOVAC 2.4 MCG/0.5 ML syringes to the Defense Logistics Agency (DLA) Troop Support Medical, a major component of the Department of Defense (DOD) responsible for providing medical supplies to military healthcare facilities. The prime contractor is Amerisourcebergen Drug Corp, a large pharmaceutical distributor and healthcare solutions provider. The contract is a firm fixed-price delivery order with a ceiling value of $3,841.86 and a period of...
The U.S. Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp's Corporate Office Division a Firm Fixed Price Delivery Order contract worth $7,427.20 for the supply of TICOVAC 2.4 MCG/0.5 ML SYRINGE 0.5ML. This contract has a completion date of July 12, 2024. Amerisourcebergen is a major pharmaceutical distributor that holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical to provide a comprehensive range of pharmaceutical products and medical...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,927.08, is a delivery order for the provision of TICOVAC 2.4 MCG/0.5 ML SYRINGE 0.5ML, a medical product. The contract has a completion date of April 23, 2025 and is a firm fixed-price arrangement. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a delivery order award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $6,477.36, is for the supply of TICOVAC 2.4 MCG/0.5 ML SYRINGE 0.5ML, a vaccine product. The award is placed against an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which is valued at $999,999,999 and runs through November 2026. This IDC serves as a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $167,107.50 firm-fixed-price contract, with a performance period through July 2024, is for the supply of TICOVAC 2.4 MCG/0.5 ML SYRINGE 0.5ML, a vaccine product. The award does not have a set-aside designation, indicating open competition. AmerisourceBergen also holds a $999,999,999 Indefinite Delivery Contract (IDC) with...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $1,958 and is a delivery order under the DLA's broader Indefinite Delivery Contract (IDC) valued at $999,999,999, which supports the provision of a comprehensive range of pharmaceutical products and medical supplies to military healthcare programs globally. The contract covers the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,564.64 Firm Fixed Price delivery order covers the procurement of TICOVAC 1.2 MCG/0.25 ML SYRING 0.25ML, a medical product. The contract has an ultimate completion date of March 18, 2025. This appears to be a delivery order under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA...
  • SPE2DB22D3501
    Indefinite Delivery Contract
  • SPE2DB22D3501-SPE2DB25FTG19
    Delivery Order

This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the delivery of TICOVAC 2.4 MCG/0.5 ML SYRINGE 0.5ML. The Firm Fixed Price contract has a ceiling value of $18,567.60 and runs through November 15, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 1/23/25, 9:02 AM